Indivior PLC (LON:INDV – Get Free Report) insider Jo Le Couilliard purchased 1,490 shares of the firm’s stock in a transaction on Friday, July 26th. The stock was acquired at an average price of GBX 1,006 ($13.01) per share, for a total transaction of £14,989.40 ($19,386.19).
Indivior Stock Up 2.7 %
INDV opened at GBX 987 ($12.77) on Monday. The company has a current ratio of 0.93, a quick ratio of 1.52 and a debt-to-equity ratio of 2,790.00. Indivior PLC has a 1-year low of GBX 653 ($8.45) and a 1-year high of GBX 1,927 ($24.92). The company has a market capitalization of £1.33 billion, a PE ratio of 32,900.00, a PEG ratio of -5.57 and a beta of 0.06. The firm’s 50 day simple moving average is GBX 1,172.64 and its two-hundred day simple moving average is GBX 1,387.37.
Wall Street Analysts Forecast Growth
Separately, Deutsche Bank Aktiengesellschaft decreased their price target on shares of Indivior from GBX 2,350 ($30.39) to GBX 1,500 ($19.40) and set a “buy” rating on the stock in a research report on Tuesday, July 9th.
About Indivior
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Further Reading
- Five stocks we like better than Indivior
- Most Volatile Stocks, What Investors Need to Know
- Is Crypto Cool Again? What Stocks You Should Be Watching
- Stock Average Calculator
- Why Call Options Volume for These 2 Stocks Spiked Together
- Where Do I Find 52-Week Highs and Lows?
- MarketBeat Week in Review – 7/22 – 7/26
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.